SIRAKOSS was granted two U.S. patents covering synthetic bone graft technologies, and is reportedly seeking to raise £3.5MM to £5.0MM (~US $4.4MM to $6.3MM) in support of U.S. and EU regulatory approvals.
U.S. Patent No. 9,492,591 describes novel formulations of putty products, in which core technology may be combined with modified resorbable polymer carriers to produce a bone graft with improved handling characteristics and enhanced efficacy. U.S. Patent No. 9,492,585 describes a range of bone graft technologies with specific microstructural properties, expanding the potential products that SIRAKOSS can develop. The company already held patents throughout Europe, Japan, Australia and China, with core IP in the U.S., Japan and Australia.
In 2014, the company secured £3.1MM (~US $4.8MM at the time) in Series A financing, supporting development of the MaxSi™ range of synthetic bone grafts.
SIRAKOSS was granted two U.S. patents covering synthetic bone graft technologies, and is reportedly seeking to raise £3.5MM to £5.0MM (~US $4.4MM to $6.3MM) in support of U.S. and EU regulatory approvals.
U.S. Patent No. 9,492,591 describes novel formulations of putty products, in which core technology may be combined with modified resorbable...
SIRAKOSS was granted two U.S. patents covering synthetic bone graft technologies, and is reportedly seeking to raise £3.5MM to £5.0MM (~US $4.4MM to $6.3MM) in support of U.S. and EU regulatory approvals.
U.S. Patent No. 9,492,591 describes novel formulations of putty products, in which core technology may be combined with modified resorbable polymer carriers to produce a bone graft with improved handling characteristics and enhanced efficacy. U.S. Patent No. 9,492,585 describes a range of bone graft technologies with specific microstructural properties, expanding the potential products that SIRAKOSS can develop. The company already held patents throughout Europe, Japan, Australia and China, with core IP in the U.S., Japan and Australia.
In 2014, the company secured £3.1MM (~US $4.8MM at the time) in Series A financing, supporting development of the MaxSi™ range of synthetic bone grafts.
Copy to clipboard 
